nodes	percent_of_prediction	percent_of_DWPC	metapath
Buprenorphine—CYP2A6—Nevirapine—acquired immunodeficiency syndrome	0.0254	0.0346	CbGbCtD
Buprenorphine—ABCG2—Nelfinavir—acquired immunodeficiency syndrome	0.0178	0.0243	CbGbCtD
Buprenorphine—CYP2A6—Zidovudine—acquired immunodeficiency syndrome	0.0167	0.0227	CbGbCtD
Buprenorphine—ABCG2—Ritonavir—acquired immunodeficiency syndrome	0.0161	0.0219	CbGbCtD
Buprenorphine—ABCG2—Saquinavir—acquired immunodeficiency syndrome	0.0161	0.0219	CbGbCtD
Buprenorphine—CYP3A7—Delavirdine—acquired immunodeficiency syndrome	0.0157	0.0214	CbGbCtD
Buprenorphine—CYP3A7-CYP3A51P—Delavirdine—acquired immunodeficiency syndrome	0.0157	0.0214	CbGbCtD
Buprenorphine—ABCG2—Zidovudine—acquired immunodeficiency syndrome	0.0155	0.021	CbGbCtD
Buprenorphine—CYP3A7—Indinavir—acquired immunodeficiency syndrome	0.0136	0.0185	CbGbCtD
Buprenorphine—CYP3A7-CYP3A51P—Indinavir—acquired immunodeficiency syndrome	0.0136	0.0185	CbGbCtD
Buprenorphine—CYP3A7—Nelfinavir—acquired immunodeficiency syndrome	0.0132	0.0179	CbGbCtD
Buprenorphine—CYP3A7-CYP3A51P—Nelfinavir—acquired immunodeficiency syndrome	0.0132	0.0179	CbGbCtD
Buprenorphine—CYP3A5—Nevirapine—acquired immunodeficiency syndrome	0.013	0.0177	CbGbCtD
Buprenorphine—ABCG2—Lamivudine—acquired immunodeficiency syndrome	0.012	0.0163	CbGbCtD
Buprenorphine—CYP3A7—Saquinavir—acquired immunodeficiency syndrome	0.0119	0.0162	CbGbCtD
Buprenorphine—CYP3A7—Ritonavir—acquired immunodeficiency syndrome	0.0119	0.0162	CbGbCtD
Buprenorphine—CYP3A7-CYP3A51P—Saquinavir—acquired immunodeficiency syndrome	0.0119	0.0162	CbGbCtD
Buprenorphine—CYP3A7-CYP3A51P—Ritonavir—acquired immunodeficiency syndrome	0.0119	0.0162	CbGbCtD
Buprenorphine—CYP3A5—Delavirdine—acquired immunodeficiency syndrome	0.0118	0.016	CbGbCtD
Buprenorphine—CYP3A5—Amprenavir—acquired immunodeficiency syndrome	0.0118	0.016	CbGbCtD
Buprenorphine—CYP2C8—Delavirdine—acquired immunodeficiency syndrome	0.0113	0.0154	CbGbCtD
Buprenorphine—CYP2C8—Amprenavir—acquired immunodeficiency syndrome	0.0113	0.0154	CbGbCtD
Buprenorphine—CYP2C19—Efavirenz—acquired immunodeficiency syndrome	0.0112	0.0152	CbGbCtD
Buprenorphine—CYP2C19—Lopinavir—acquired immunodeficiency syndrome	0.0105	0.0143	CbGbCtD
Buprenorphine—CYP1A2—Efavirenz—acquired immunodeficiency syndrome	0.0103	0.014	CbGbCtD
Buprenorphine—CYP3A5—Indinavir—acquired immunodeficiency syndrome	0.0102	0.0138	CbGbCtD
Buprenorphine—CYP3A5—Nelfinavir—acquired immunodeficiency syndrome	0.00989	0.0134	CbGbCtD
Buprenorphine—CYP1A2—Nevirapine—acquired immunodeficiency syndrome	0.00971	0.0132	CbGbCtD
Buprenorphine—CYP1A2—Lopinavir—acquired immunodeficiency syndrome	0.00971	0.0132	CbGbCtD
Buprenorphine—CYP2C19—Delavirdine—acquired immunodeficiency syndrome	0.00952	0.0129	CbGbCtD
Buprenorphine—CYP2C19—Amprenavir—acquired immunodeficiency syndrome	0.00952	0.0129	CbGbCtD
Buprenorphine—CYP2C9—Efavirenz—acquired immunodeficiency syndrome	0.00931	0.0126	CbGbCtD
Buprenorphine—CYP3A5—Saquinavir—acquired immunodeficiency syndrome	0.00894	0.0122	CbGbCtD
Buprenorphine—CYP3A5—Ritonavir—acquired immunodeficiency syndrome	0.00894	0.0122	CbGbCtD
Buprenorphine—CYP1A2—Delavirdine—acquired immunodeficiency syndrome	0.00878	0.0119	CbGbCtD
Buprenorphine—CYP2C9—Lopinavir—acquired immunodeficiency syndrome	0.00875	0.0119	CbGbCtD
Buprenorphine—CYP2C9—Nevirapine—acquired immunodeficiency syndrome	0.00875	0.0119	CbGbCtD
Buprenorphine—CYP2C8—Ritonavir—acquired immunodeficiency syndrome	0.0086	0.0117	CbGbCtD
Buprenorphine—CYP2C8—Saquinavir—acquired immunodeficiency syndrome	0.0086	0.0117	CbGbCtD
Buprenorphine—CYP2D6—Efavirenz—acquired immunodeficiency syndrome	0.00851	0.0116	CbGbCtD
Buprenorphine—ABCB1—Lopinavir—acquired immunodeficiency syndrome	0.00849	0.0115	CbGbCtD
Buprenorphine—CYP2C8—Zidovudine—acquired immunodeficiency syndrome	0.00824	0.0112	CbGbCtD
Buprenorphine—CYP2C19—Indinavir—acquired immunodeficiency syndrome	0.00822	0.0112	CbGbCtD
Buprenorphine—CYP2D6—Nevirapine—acquired immunodeficiency syndrome	0.008	0.0109	CbGbCtD
Buprenorphine—CYP2D6—Lopinavir—acquired immunodeficiency syndrome	0.008	0.0109	CbGbCtD
Buprenorphine—CYP2C19—Nelfinavir—acquired immunodeficiency syndrome	0.00798	0.0108	CbGbCtD
Buprenorphine—CYP2C9—Delavirdine—acquired immunodeficiency syndrome	0.00791	0.0108	CbGbCtD
Buprenorphine—CYP2C9—Amprenavir—acquired immunodeficiency syndrome	0.00791	0.0108	CbGbCtD
Buprenorphine—ABCB1—Amprenavir—acquired immunodeficiency syndrome	0.00768	0.0104	CbGbCtD
Buprenorphine—CYP1A2—Nelfinavir—acquired immunodeficiency syndrome	0.00736	0.01	CbGbCtD
Buprenorphine—CYP2D6—Delavirdine—acquired immunodeficiency syndrome	0.00724	0.00983	CbGbCtD
Buprenorphine—CYP2D6—Amprenavir—acquired immunodeficiency syndrome	0.00724	0.00983	CbGbCtD
Buprenorphine—CYP2C19—Ritonavir—acquired immunodeficiency syndrome	0.00721	0.0098	CbGbCtD
Buprenorphine—CYP2C19—Saquinavir—acquired immunodeficiency syndrome	0.00721	0.0098	CbGbCtD
Buprenorphine—CYP2C19—Zidovudine—acquired immunodeficiency syndrome	0.00692	0.0094	CbGbCtD
Buprenorphine—CYP2C9—Indinavir—acquired immunodeficiency syndrome	0.00683	0.00928	CbGbCtD
Buprenorphine—CYP1A2—Ritonavir—acquired immunodeficiency syndrome	0.00666	0.00905	CbGbCtD
Buprenorphine—CYP2C9—Nelfinavir—acquired immunodeficiency syndrome	0.00663	0.00901	CbGbCtD
Buprenorphine—ABCB1—Indinavir—acquired immunodeficiency syndrome	0.00663	0.00901	CbGbCtD
Buprenorphine—ABCB1—Nelfinavir—acquired immunodeficiency syndrome	0.00644	0.00875	CbGbCtD
Buprenorphine—CYP2D6—Indinavir—acquired immunodeficiency syndrome	0.00625	0.00849	CbGbCtD
Buprenorphine—CYP2D6—Nelfinavir—acquired immunodeficiency syndrome	0.00606	0.00824	CbGbCtD
Buprenorphine—CYP2C9—Saquinavir—acquired immunodeficiency syndrome	0.006	0.00815	CbGbCtD
Buprenorphine—CYP2C9—Ritonavir—acquired immunodeficiency syndrome	0.006	0.00815	CbGbCtD
Buprenorphine—ABCB1—Saquinavir—acquired immunodeficiency syndrome	0.00582	0.00791	CbGbCtD
Buprenorphine—ABCB1—Ritonavir—acquired immunodeficiency syndrome	0.00582	0.00791	CbGbCtD
Buprenorphine—CYP2C9—Zidovudine—acquired immunodeficiency syndrome	0.00575	0.00781	CbGbCtD
Buprenorphine—ABCB1—Zidovudine—acquired immunodeficiency syndrome	0.00558	0.00758	CbGbCtD
Buprenorphine—CYP2D6—Saquinavir—acquired immunodeficiency syndrome	0.00548	0.00745	CbGbCtD
Buprenorphine—CYP2D6—Ritonavir—acquired immunodeficiency syndrome	0.00548	0.00745	CbGbCtD
Buprenorphine—CYP3A4—Efavirenz—acquired immunodeficiency syndrome	0.00541	0.00735	CbGbCtD
Buprenorphine—CYP3A4—Nevirapine—acquired immunodeficiency syndrome	0.00509	0.00691	CbGbCtD
Buprenorphine—CYP3A4—Lopinavir—acquired immunodeficiency syndrome	0.00509	0.00691	CbGbCtD
Buprenorphine—CYP3A4—Amprenavir—acquired immunodeficiency syndrome	0.0046	0.00625	CbGbCtD
Buprenorphine—CYP3A4—Delavirdine—acquired immunodeficiency syndrome	0.0046	0.00625	CbGbCtD
Buprenorphine—ABCB1—Lamivudine—acquired immunodeficiency syndrome	0.00432	0.00587	CbGbCtD
Buprenorphine—CYP3A4—Indinavir—acquired immunodeficiency syndrome	0.00397	0.0054	CbGbCtD
Buprenorphine—CYP3A4—Nelfinavir—acquired immunodeficiency syndrome	0.00386	0.00524	CbGbCtD
Buprenorphine—CYP3A4—Saquinavir—acquired immunodeficiency syndrome	0.00349	0.00474	CbGbCtD
Buprenorphine—CYP3A4—Ritonavir—acquired immunodeficiency syndrome	0.00349	0.00474	CbGbCtD
Buprenorphine—CYP3A4—Zidovudine—acquired immunodeficiency syndrome	0.00334	0.00454	CbGbCtD
Buprenorphine—OPRM1—nerve—acquired immunodeficiency syndrome	0.00187	0.0532	CbGeAlD
Buprenorphine—OPRL1—lymphoid tissue—acquired immunodeficiency syndrome	0.00157	0.0446	CbGeAlD
Buprenorphine—OPRL1—blood—acquired immunodeficiency syndrome	0.00147	0.042	CbGeAlD
Buprenorphine—OPRL1—spinal cord—acquired immunodeficiency syndrome	0.00142	0.0404	CbGeAlD
Buprenorphine—OPRL1—nervous system—acquired immunodeficiency syndrome	0.0012	0.0341	CbGeAlD
Buprenorphine—OPRL1—central nervous system—acquired immunodeficiency syndrome	0.00115	0.0328	CbGeAlD
Buprenorphine—UGT1A9—digestive system—acquired immunodeficiency syndrome	0.00101	0.0287	CbGeAlD
Buprenorphine—CYP2C19—blood plasma—acquired immunodeficiency syndrome	0.000973	0.0277	CbGeAlD
Buprenorphine—OPRL1—brain—acquired immunodeficiency syndrome	0.000914	0.026	CbGeAlD
Buprenorphine—OPRL1—lymph node—acquired immunodeficiency syndrome	0.000883	0.0252	CbGeAlD
Buprenorphine—CYP2C18—digestive system—acquired immunodeficiency syndrome	0.000881	0.0251	CbGeAlD
Buprenorphine—CYP2C8—blood plasma—acquired immunodeficiency syndrome	0.00085	0.0242	CbGeAlD
Buprenorphine—CYP1A2—blood plasma—acquired immunodeficiency syndrome	0.000795	0.0227	CbGeAlD
Buprenorphine—CYP2C18—vagina—acquired immunodeficiency syndrome	0.000778	0.0222	CbGeAlD
Buprenorphine—CYP3A5—blood plasma—acquired immunodeficiency syndrome	0.000767	0.0219	CbGeAlD
Buprenorphine—CYP2C9—blood plasma—acquired immunodeficiency syndrome	0.000755	0.0215	CbGeAlD
Buprenorphine—OPRD1—nervous system—acquired immunodeficiency syndrome	0.000616	0.0176	CbGeAlD
Buprenorphine—OPRD1—central nervous system—acquired immunodeficiency syndrome	0.000593	0.0169	CbGeAlD
Buprenorphine—OPRK1—nervous system—acquired immunodeficiency syndrome	0.000591	0.0168	CbGeAlD
Buprenorphine—CYP3A4—blood plasma—acquired immunodeficiency syndrome	0.000575	0.0164	CbGeAlD
Buprenorphine—OPRK1—central nervous system—acquired immunodeficiency syndrome	0.000569	0.0162	CbGeAlD
Buprenorphine—CYP2D6—blood plasma—acquired immunodeficiency syndrome	0.000566	0.0161	CbGeAlD
Buprenorphine—OPRM1—blood—acquired immunodeficiency syndrome	0.000517	0.0147	CbGeAlD
Buprenorphine—CYP2A6—vagina—acquired immunodeficiency syndrome	0.000514	0.0146	CbGeAlD
Buprenorphine—OPRM1—spinal cord—acquired immunodeficiency syndrome	0.000499	0.0142	CbGeAlD
Buprenorphine—CYP2A6—lung—acquired immunodeficiency syndrome	0.000486	0.0139	CbGeAlD
Buprenorphine—OPRD1—brain—acquired immunodeficiency syndrome	0.000471	0.0134	CbGeAlD
Buprenorphine—OPRK1—brain—acquired immunodeficiency syndrome	0.000451	0.0129	CbGeAlD
Buprenorphine—OPRM1—nervous system—acquired immunodeficiency syndrome	0.00042	0.012	CbGeAlD
Buprenorphine—ABCB1—blood plasma—acquired immunodeficiency syndrome	0.000407	0.0116	CbGeAlD
Buprenorphine—OPRM1—central nervous system—acquired immunodeficiency syndrome	0.000404	0.0115	CbGeAlD
Buprenorphine—CYP2C19—digestive system—acquired immunodeficiency syndrome	0.000374	0.0107	CbGeAlD
Buprenorphine—CYP2C19—blood—acquired immunodeficiency syndrome	0.000357	0.0102	CbGeAlD
Buprenorphine—CYP2A6—brain—acquired immunodeficiency syndrome	0.000344	0.0098	CbGeAlD
Buprenorphine—CYP2C19—vagina—acquired immunodeficiency syndrome	0.000331	0.00942	CbGeAlD
Buprenorphine—OPRM1—brain—acquired immunodeficiency syndrome	0.000321	0.00915	CbGeAlD
Buprenorphine—CYP2C8—blood—acquired immunodeficiency syndrome	0.000311	0.00887	CbGeAlD
Buprenorphine—CYP1A2—digestive system—acquired immunodeficiency syndrome	0.000306	0.00871	CbGeAlD
Buprenorphine—ABCG2—blood—acquired immunodeficiency syndrome	0.000303	0.00862	CbGeAlD
Buprenorphine—CYP3A5—digestive system—acquired immunodeficiency syndrome	0.000295	0.0084	CbGeAlD
Buprenorphine—ABCG2—bone marrow—acquired immunodeficiency syndrome	0.000293	0.00834	CbGeAlD
Buprenorphine—ABCG2—spinal cord—acquired immunodeficiency syndrome	0.000292	0.00831	CbGeAlD
Buprenorphine—CYP1A2—blood—acquired immunodeficiency syndrome	0.000291	0.0083	CbGeAlD
Buprenorphine—CYP2C9—digestive system—acquired immunodeficiency syndrome	0.00029	0.00827	CbGeAlD
Buprenorphine—CYP2C8—vagina—acquired immunodeficiency syndrome	0.000289	0.00822	CbGeAlD
Buprenorphine—CYP3A5—blood—acquired immunodeficiency syndrome	0.000281	0.00801	CbGeAlD
Buprenorphine—ABCG2—vagina—acquired immunodeficiency syndrome	0.000281	0.00799	CbGeAlD
Buprenorphine—CYP2C9—blood—acquired immunodeficiency syndrome	0.000276	0.00788	CbGeAlD
Buprenorphine—ABCG2—lung—acquired immunodeficiency syndrome	0.000265	0.00756	CbGeAlD
Buprenorphine—CYP3A5—vagina—acquired immunodeficiency syndrome	0.00026	0.00742	CbGeAlD
Buprenorphine—CYP1A2—lung—acquired immunodeficiency syndrome	0.000255	0.00728	CbGeAlD
Buprenorphine—CYP3A5—lung—acquired immunodeficiency syndrome	0.000246	0.00702	CbGeAlD
Buprenorphine—ABCB1—retina—acquired immunodeficiency syndrome	0.000223	0.00636	CbGeAlD
Buprenorphine—CYP3A4—digestive system—acquired immunodeficiency syndrome	0.000221	0.00631	CbGeAlD
Buprenorphine—CYP2D6—digestive system—acquired immunodeficiency syndrome	0.000218	0.00621	CbGeAlD
Buprenorphine—CYP3A4—blood—acquired immunodeficiency syndrome	0.000211	0.00601	CbGeAlD
Buprenorphine—CYP2D6—blood—acquired immunodeficiency syndrome	0.000207	0.00591	CbGeAlD
Buprenorphine—CYP2C8—brain—acquired immunodeficiency syndrome	0.000193	0.0055	CbGeAlD
Buprenorphine—ABCG2—brain—acquired immunodeficiency syndrome	0.000188	0.00535	CbGeAlD
Buprenorphine—ABCG2—lymph node—acquired immunodeficiency syndrome	0.000181	0.00517	CbGeAlD
Buprenorphine—CYP3A4—nervous system—acquired immunodeficiency syndrome	0.000171	0.00488	CbGeAlD
Buprenorphine—CYP2D6—nervous system—acquired immunodeficiency syndrome	0.000168	0.0048	CbGeAlD
Buprenorphine—CYP3A4—central nervous system—acquired immunodeficiency syndrome	0.000165	0.0047	CbGeAlD
Buprenorphine—CYP2D6—central nervous system—acquired immunodeficiency syndrome	0.000162	0.00462	CbGeAlD
Buprenorphine—ABCB1—lymphoid tissue—acquired immunodeficiency syndrome	0.000159	0.00452	CbGeAlD
Buprenorphine—ABCB1—digestive system—acquired immunodeficiency syndrome	0.000157	0.00446	CbGeAlD
Buprenorphine—ABCB1—blood—acquired immunodeficiency syndrome	0.000149	0.00425	CbGeAlD
Buprenorphine—ABCB1—bone marrow—acquired immunodeficiency syndrome	0.000144	0.00411	CbGeAlD
Buprenorphine—ABCB1—spinal cord—acquired immunodeficiency syndrome	0.000144	0.0041	CbGeAlD
Buprenorphine—ABCB1—vagina—acquired immunodeficiency syndrome	0.000138	0.00394	CbGeAlD
Buprenorphine—ABCB1—lung—acquired immunodeficiency syndrome	0.000131	0.00373	CbGeAlD
Buprenorphine—CYP2D6—brain—acquired immunodeficiency syndrome	0.000129	0.00367	CbGeAlD
Buprenorphine—ABCB1—nervous system—acquired immunodeficiency syndrome	0.000121	0.00345	CbGeAlD
Buprenorphine—ABCB1—central nervous system—acquired immunodeficiency syndrome	0.000117	0.00332	CbGeAlD
Buprenorphine—Myalgia—Ritonavir—acquired immunodeficiency syndrome	0.000107	0.000558	CcSEcCtD
Buprenorphine—Decreased appetite—Indinavir—acquired immunodeficiency syndrome	0.000106	0.000556	CcSEcCtD
Buprenorphine—Anxiety—Ritonavir—acquired immunodeficiency syndrome	0.000106	0.000556	CcSEcCtD
Buprenorphine—Loss of consciousness—Saquinavir—acquired immunodeficiency syndrome	0.000106	0.000554	CcSEcCtD
Buprenorphine—Unspecified disorder of skin and subcutaneous tissue—Ritonavir—acquired immunodeficiency syndrome	0.000106	0.000554	CcSEcCtD
Buprenorphine—Gastrointestinal disorder—Indinavir—acquired immunodeficiency syndrome	0.000105	0.000552	CcSEcCtD
Buprenorphine—Pruritus—Abacavir—acquired immunodeficiency syndrome	0.000105	0.000552	CcSEcCtD
Buprenorphine—Fatigue—Indinavir—acquired immunodeficiency syndrome	0.000105	0.000552	CcSEcCtD
Buprenorphine—Anorexia—Delavirdine—acquired immunodeficiency syndrome	0.000105	0.000551	CcSEcCtD
Buprenorphine—Discomfort—Ritonavir—acquired immunodeficiency syndrome	0.000105	0.000551	CcSEcCtD
Buprenorphine—Musculoskeletal discomfort—Efavirenz—acquired immunodeficiency syndrome	0.000105	0.000551	CcSEcCtD
Buprenorphine—Cough—Saquinavir—acquired immunodeficiency syndrome	0.000105	0.000551	CcSEcCtD
Buprenorphine—Angioedema—Lamivudine—acquired immunodeficiency syndrome	0.000105	0.00055	CcSEcCtD
Buprenorphine—Pain—Indinavir—acquired immunodeficiency syndrome	0.000104	0.000547	CcSEcCtD
Buprenorphine—Constipation—Indinavir—acquired immunodeficiency syndrome	0.000104	0.000547	CcSEcCtD
Buprenorphine—Insomnia—Efavirenz—acquired immunodeficiency syndrome	0.000104	0.000547	CcSEcCtD
Buprenorphine—Urticaria—Zidovudine—acquired immunodeficiency syndrome	0.000104	0.000547	CcSEcCtD
Buprenorphine—Convulsion—Saquinavir—acquired immunodeficiency syndrome	0.000104	0.000547	CcSEcCtD
Buprenorphine—Dry mouth—Ritonavir—acquired immunodeficiency syndrome	0.000104	0.000546	CcSEcCtD
Buprenorphine—Hypertension—Saquinavir—acquired immunodeficiency syndrome	0.000104	0.000545	CcSEcCtD
Buprenorphine—Abdominal pain—Zidovudine—acquired immunodeficiency syndrome	0.000104	0.000544	CcSEcCtD
Buprenorphine—Body temperature increased—Zidovudine—acquired immunodeficiency syndrome	0.000104	0.000544	CcSEcCtD
Buprenorphine—Diarrhoea—Nelfinavir—acquired immunodeficiency syndrome	0.000104	0.000543	CcSEcCtD
Buprenorphine—Paraesthesia—Efavirenz—acquired immunodeficiency syndrome	0.000104	0.000543	CcSEcCtD
Buprenorphine—Malaise—Lamivudine—acquired immunodeficiency syndrome	0.000104	0.000543	CcSEcCtD
Buprenorphine—Diarrhoea—Stavudine—acquired immunodeficiency syndrome	0.000103	0.000542	CcSEcCtD
Buprenorphine—Nausea—Didanosine—acquired immunodeficiency syndrome	0.000103	0.000542	CcSEcCtD
Buprenorphine—Vertigo—Lamivudine—acquired immunodeficiency syndrome	0.000103	0.000541	CcSEcCtD
Buprenorphine—Hypotension—Delavirdine—acquired immunodeficiency syndrome	0.000103	0.000541	CcSEcCtD
Buprenorphine—Syncope—Lamivudine—acquired immunodeficiency syndrome	0.000103	0.00054	CcSEcCtD
Buprenorphine—Confusional state—Ritonavir—acquired immunodeficiency syndrome	0.000103	0.000539	CcSEcCtD
Buprenorphine—Dyspnoea—Efavirenz—acquired immunodeficiency syndrome	0.000103	0.000539	CcSEcCtD
Buprenorphine—Somnolence—Efavirenz—acquired immunodeficiency syndrome	0.000103	0.000537	CcSEcCtD
Buprenorphine—Myalgia—Saquinavir—acquired immunodeficiency syndrome	0.000103	0.000537	CcSEcCtD
Buprenorphine—Arthralgia—Saquinavir—acquired immunodeficiency syndrome	0.000103	0.000537	CcSEcCtD
Buprenorphine—Chest pain—Saquinavir—acquired immunodeficiency syndrome	0.000103	0.000537	CcSEcCtD
Buprenorphine—Anxiety—Saquinavir—acquired immunodeficiency syndrome	0.000102	0.000535	CcSEcCtD
Buprenorphine—Oedema—Ritonavir—acquired immunodeficiency syndrome	0.000102	0.000535	CcSEcCtD
Buprenorphine—Diarrhoea—Abacavir—acquired immunodeficiency syndrome	0.000102	0.000534	CcSEcCtD
Buprenorphine—Unspecified disorder of skin and subcutaneous tissue—Saquinavir—acquired immunodeficiency syndrome	0.000102	0.000533	CcSEcCtD
Buprenorphine—Dyspepsia—Efavirenz—acquired immunodeficiency syndrome	0.000102	0.000532	CcSEcCtD
Buprenorphine—Discomfort—Saquinavir—acquired immunodeficiency syndrome	0.000101	0.000531	CcSEcCtD
Buprenorphine—Loss of consciousness—Lamivudine—acquired immunodeficiency syndrome	0.000101	0.000529	CcSEcCtD
Buprenorphine—Feeling abnormal—Indinavir—acquired immunodeficiency syndrome	0.000101	0.000527	CcSEcCtD
Buprenorphine—Musculoskeletal discomfort—Delavirdine—acquired immunodeficiency syndrome	0.000101	0.000527	CcSEcCtD
Buprenorphine—Shock—Ritonavir—acquired immunodeficiency syndrome	0.0001	0.000526	CcSEcCtD
Buprenorphine—Decreased appetite—Efavirenz—acquired immunodeficiency syndrome	0.0001	0.000526	CcSEcCtD
Buprenorphine—Dry mouth—Saquinavir—acquired immunodeficiency syndrome	0.0001	0.000525	CcSEcCtD
Buprenorphine—Cough—Lamivudine—acquired immunodeficiency syndrome	0.0001	0.000525	CcSEcCtD
Buprenorphine—Dizziness—Nelfinavir—acquired immunodeficiency syndrome	0.0001	0.000525	CcSEcCtD
Buprenorphine—Nervous system disorder—Ritonavir—acquired immunodeficiency syndrome	0.0001	0.000525	CcSEcCtD
Buprenorphine—Dizziness—Stavudine—acquired immunodeficiency syndrome	9.99e-05	0.000523	CcSEcCtD
Buprenorphine—Gastrointestinal pain—Indinavir—acquired immunodeficiency syndrome	9.99e-05	0.000523	CcSEcCtD
Buprenorphine—Insomnia—Delavirdine—acquired immunodeficiency syndrome	9.99e-05	0.000523	CcSEcCtD
Buprenorphine—Tachycardia—Ritonavir—acquired immunodeficiency syndrome	9.97e-05	0.000522	CcSEcCtD
Buprenorphine—Gastrointestinal disorder—Efavirenz—acquired immunodeficiency syndrome	9.96e-05	0.000522	CcSEcCtD
Buprenorphine—Convulsion—Lamivudine—acquired immunodeficiency syndrome	9.95e-05	0.000521	CcSEcCtD
Buprenorphine—Vomiting—Nevirapine—acquired immunodeficiency syndrome	9.95e-05	0.000521	CcSEcCtD
Buprenorphine—Fatigue—Efavirenz—acquired immunodeficiency syndrome	9.95e-05	0.000521	CcSEcCtD
Buprenorphine—Skin disorder—Ritonavir—acquired immunodeficiency syndrome	9.92e-05	0.00052	CcSEcCtD
Buprenorphine—Paraesthesia—Delavirdine—acquired immunodeficiency syndrome	9.91e-05	0.000519	CcSEcCtD
Buprenorphine—Confusional state—Saquinavir—acquired immunodeficiency syndrome	9.91e-05	0.000519	CcSEcCtD
Buprenorphine—Hyperhidrosis—Ritonavir—acquired immunodeficiency syndrome	9.87e-05	0.000517	CcSEcCtD
Buprenorphine—Constipation—Efavirenz—acquired immunodeficiency syndrome	9.87e-05	0.000517	CcSEcCtD
Buprenorphine—Pain—Efavirenz—acquired immunodeficiency syndrome	9.87e-05	0.000517	CcSEcCtD
Buprenorphine—Rash—Nevirapine—acquired immunodeficiency syndrome	9.87e-05	0.000517	CcSEcCtD
Buprenorphine—Dermatitis—Nevirapine—acquired immunodeficiency syndrome	9.86e-05	0.000516	CcSEcCtD
Buprenorphine—Dyspnoea—Delavirdine—acquired immunodeficiency syndrome	9.84e-05	0.000516	CcSEcCtD
Buprenorphine—Dizziness—Abacavir—acquired immunodeficiency syndrome	9.84e-05	0.000516	CcSEcCtD
Buprenorphine—Oedema—Saquinavir—acquired immunodeficiency syndrome	9.83e-05	0.000515	CcSEcCtD
Buprenorphine—Somnolence—Delavirdine—acquired immunodeficiency syndrome	9.82e-05	0.000514	CcSEcCtD
Buprenorphine—Headache—Nevirapine—acquired immunodeficiency syndrome	9.8e-05	0.000514	CcSEcCtD
Buprenorphine—Myalgia—Lamivudine—acquired immunodeficiency syndrome	9.78e-05	0.000512	CcSEcCtD
Buprenorphine—Chest pain—Lamivudine—acquired immunodeficiency syndrome	9.78e-05	0.000512	CcSEcCtD
Buprenorphine—Arthralgia—Lamivudine—acquired immunodeficiency syndrome	9.78e-05	0.000512	CcSEcCtD
Buprenorphine—OPRK1—G alpha (i) signalling events—CXCR4—acquired immunodeficiency syndrome	9.77e-05	0.00255	CbGpPWpGaD
Buprenorphine—OPRK1—G alpha (i) signalling events—CXCL12—acquired immunodeficiency syndrome	9.77e-05	0.00255	CbGpPWpGaD
Buprenorphine—Infection—Saquinavir—acquired immunodeficiency syndrome	9.76e-05	0.000512	CcSEcCtD
Buprenorphine—Anxiety—Lamivudine—acquired immunodeficiency syndrome	9.75e-05	0.000511	CcSEcCtD
Buprenorphine—Anorexia—Ritonavir—acquired immunodeficiency syndrome	9.73e-05	0.00051	CcSEcCtD
Buprenorphine—Dyspepsia—Delavirdine—acquired immunodeficiency syndrome	9.72e-05	0.000509	CcSEcCtD
Buprenorphine—Unspecified disorder of skin and subcutaneous tissue—Lamivudine—acquired immunodeficiency syndrome	9.71e-05	0.000509	CcSEcCtD
Buprenorphine—Urticaria—Indinavir—acquired immunodeficiency syndrome	9.7e-05	0.000508	CcSEcCtD
Buprenorphine—Shock—Saquinavir—acquired immunodeficiency syndrome	9.67e-05	0.000507	CcSEcCtD
Buprenorphine—Discomfort—Lamivudine—acquired immunodeficiency syndrome	9.66e-05	0.000506	CcSEcCtD
Buprenorphine—Abdominal pain—Indinavir—acquired immunodeficiency syndrome	9.66e-05	0.000506	CcSEcCtD
Buprenorphine—Body temperature increased—Indinavir—acquired immunodeficiency syndrome	9.66e-05	0.000506	CcSEcCtD
Buprenorphine—OPRK1—GPCRs, Class A Rhodopsin-like—CCR2—acquired immunodeficiency syndrome	9.64e-05	0.00252	CbGpPWpGaD
Buprenorphine—Nervous system disorder—Saquinavir—acquired immunodeficiency syndrome	9.64e-05	0.000505	CcSEcCtD
Buprenorphine—Vomiting—Nelfinavir—acquired immunodeficiency syndrome	9.64e-05	0.000505	CcSEcCtD
Buprenorphine—Vomiting—Stavudine—acquired immunodeficiency syndrome	9.61e-05	0.000503	CcSEcCtD
Buprenorphine—Decreased appetite—Delavirdine—acquired immunodeficiency syndrome	9.6e-05	0.000503	CcSEcCtD
Buprenorphine—Dry mouth—Lamivudine—acquired immunodeficiency syndrome	9.57e-05	0.000501	CcSEcCtD
Buprenorphine—Rash—Nelfinavir—acquired immunodeficiency syndrome	9.56e-05	0.000501	CcSEcCtD
Buprenorphine—Dermatitis—Nelfinavir—acquired immunodeficiency syndrome	9.55e-05	0.0005	CcSEcCtD
Buprenorphine—Skin disorder—Saquinavir—acquired immunodeficiency syndrome	9.55e-05	0.0005	CcSEcCtD
Buprenorphine—Hypotension—Ritonavir—acquired immunodeficiency syndrome	9.54e-05	0.0005	CcSEcCtD
Buprenorphine—OPRK1—Signaling by GPCR—CCL3L1—acquired immunodeficiency syndrome	9.53e-05	0.00249	CbGpPWpGaD
Buprenorphine—OPRL1—Signaling by GPCR—CCL3—acquired immunodeficiency syndrome	9.53e-05	0.00249	CbGpPWpGaD
Buprenorphine—Gastrointestinal disorder—Delavirdine—acquired immunodeficiency syndrome	9.53e-05	0.000499	CcSEcCtD
Buprenorphine—Rash—Stavudine—acquired immunodeficiency syndrome	9.53e-05	0.000499	CcSEcCtD
Buprenorphine—Fatigue—Delavirdine—acquired immunodeficiency syndrome	9.52e-05	0.000499	CcSEcCtD
Buprenorphine—Dermatitis—Stavudine—acquired immunodeficiency syndrome	9.52e-05	0.000499	CcSEcCtD
Buprenorphine—OPRM1—GPCR ligand binding—ACKR1—acquired immunodeficiency syndrome	9.51e-05	0.00249	CbGpPWpGaD
Buprenorphine—Feeling abnormal—Efavirenz—acquired immunodeficiency syndrome	9.51e-05	0.000498	CcSEcCtD
Buprenorphine—Hyperhidrosis—Saquinavir—acquired immunodeficiency syndrome	9.5e-05	0.000498	CcSEcCtD
Buprenorphine—Headache—Nelfinavir—acquired immunodeficiency syndrome	9.5e-05	0.000497	CcSEcCtD
Buprenorphine—OPRL1—GPCR downstream signaling—CCR2—acquired immunodeficiency syndrome	9.49e-05	0.00248	CbGpPWpGaD
Buprenorphine—Headache—Stavudine—acquired immunodeficiency syndrome	9.47e-05	0.000496	CcSEcCtD
Buprenorphine—Vomiting—Abacavir—acquired immunodeficiency syndrome	9.46e-05	0.000496	CcSEcCtD
Buprenorphine—Confusional state—Lamivudine—acquired immunodeficiency syndrome	9.45e-05	0.000495	CcSEcCtD
Buprenorphine—Pain—Delavirdine—acquired immunodeficiency syndrome	9.44e-05	0.000495	CcSEcCtD
Buprenorphine—Constipation—Delavirdine—acquired immunodeficiency syndrome	9.44e-05	0.000495	CcSEcCtD
Buprenorphine—Gastrointestinal pain—Efavirenz—acquired immunodeficiency syndrome	9.44e-05	0.000494	CcSEcCtD
Buprenorphine—Asthenia—Zidovudine—acquired immunodeficiency syndrome	9.42e-05	0.000494	CcSEcCtD
Buprenorphine—OPRD1—Class A/1 (Rhodopsin-like receptors)—CCR2—acquired immunodeficiency syndrome	9.42e-05	0.00246	CbGpPWpGaD
Buprenorphine—Rash—Abacavir—acquired immunodeficiency syndrome	9.39e-05	0.000492	CcSEcCtD
Buprenorphine—Dermatitis—Abacavir—acquired immunodeficiency syndrome	9.38e-05	0.000491	CcSEcCtD
Buprenorphine—Anaphylactic shock—Lamivudine—acquired immunodeficiency syndrome	9.38e-05	0.000491	CcSEcCtD
Buprenorphine—Oedema—Lamivudine—acquired immunodeficiency syndrome	9.38e-05	0.000491	CcSEcCtD
Buprenorphine—Anorexia—Saquinavir—acquired immunodeficiency syndrome	9.37e-05	0.000491	CcSEcCtD
Buprenorphine—Headache—Abacavir—acquired immunodeficiency syndrome	9.33e-05	0.000489	CcSEcCtD
Buprenorphine—Infection—Lamivudine—acquired immunodeficiency syndrome	9.31e-05	0.000488	CcSEcCtD
Buprenorphine—Musculoskeletal discomfort—Ritonavir—acquired immunodeficiency syndrome	9.3e-05	0.000487	CcSEcCtD
Buprenorphine—Nausea—Nevirapine—acquired immunodeficiency syndrome	9.3e-05	0.000487	CcSEcCtD
Buprenorphine—Pruritus—Zidovudine—acquired immunodeficiency syndrome	9.29e-05	0.000487	CcSEcCtD
Buprenorphine—ABCB1—Allograft Rejection—CXCL12—acquired immunodeficiency syndrome	9.26e-05	0.00242	CbGpPWpGaD
Buprenorphine—ABCB1—brain—acquired immunodeficiency syndrome	9.26e-05	0.00264	CbGeAlD
Buprenorphine—Insomnia—Ritonavir—acquired immunodeficiency syndrome	9.24e-05	0.000484	CcSEcCtD
Buprenorphine—Shock—Lamivudine—acquired immunodeficiency syndrome	9.22e-05	0.000483	CcSEcCtD
Buprenorphine—Nervous system disorder—Lamivudine—acquired immunodeficiency syndrome	9.19e-05	0.000482	CcSEcCtD
Buprenorphine—Hypotension—Saquinavir—acquired immunodeficiency syndrome	9.18e-05	0.000481	CcSEcCtD
Buprenorphine—Paraesthesia—Ritonavir—acquired immunodeficiency syndrome	9.17e-05	0.00048	CcSEcCtD
Buprenorphine—Urticaria—Efavirenz—acquired immunodeficiency syndrome	9.17e-05	0.00048	CcSEcCtD
Buprenorphine—OPRK1—Class A/1 (Rhodopsin-like receptors)—CCL3—acquired immunodeficiency syndrome	9.13e-05	0.00239	CbGpPWpGaD
Buprenorphine—Body temperature increased—Efavirenz—acquired immunodeficiency syndrome	9.12e-05	0.000478	CcSEcCtD
Buprenorphine—Abdominal pain—Efavirenz—acquired immunodeficiency syndrome	9.12e-05	0.000478	CcSEcCtD
Buprenorphine—OPRL1—Signaling Pathways—CCNT1—acquired immunodeficiency syndrome	9.12e-05	0.00238	CbGpPWpGaD
Buprenorphine—OPRL1—Signaling Pathways—ACKR1—acquired immunodeficiency syndrome	9.12e-05	0.00238	CbGpPWpGaD
Buprenorphine—Skin disorder—Lamivudine—acquired immunodeficiency syndrome	9.11e-05	0.000477	CcSEcCtD
Buprenorphine—Dyspnoea—Ritonavir—acquired immunodeficiency syndrome	9.1e-05	0.000477	CcSEcCtD
Buprenorphine—Feeling abnormal—Delavirdine—acquired immunodeficiency syndrome	9.1e-05	0.000477	CcSEcCtD
Buprenorphine—Somnolence—Ritonavir—acquired immunodeficiency syndrome	9.08e-05	0.000476	CcSEcCtD
Buprenorphine—Hyperhidrosis—Lamivudine—acquired immunodeficiency syndrome	9.06e-05	0.000475	CcSEcCtD
Buprenorphine—OPRK1—GPCRs, Class A Rhodopsin-like—CXCR4—acquired immunodeficiency syndrome	9.06e-05	0.00237	CbGpPWpGaD
Buprenorphine—OPRD1—Peptide ligand-binding receptors—CCR5—acquired immunodeficiency syndrome	9.05e-05	0.00236	CbGpPWpGaD
Buprenorphine—Gastrointestinal pain—Delavirdine—acquired immunodeficiency syndrome	9.03e-05	0.000473	CcSEcCtD
Buprenorphine—Nausea—Nelfinavir—acquired immunodeficiency syndrome	9e-05	0.000472	CcSEcCtD
Buprenorphine—Hypersensitivity—Indinavir—acquired immunodeficiency syndrome	9e-05	0.000471	CcSEcCtD
Buprenorphine—Dyspepsia—Ritonavir—acquired immunodeficiency syndrome	8.99e-05	0.000471	CcSEcCtD
Buprenorphine—Diarrhoea—Zidovudine—acquired immunodeficiency syndrome	8.99e-05	0.000471	CcSEcCtD
Buprenorphine—Nausea—Stavudine—acquired immunodeficiency syndrome	8.98e-05	0.00047	CcSEcCtD
Buprenorphine—UGT1A9—Aryl Hydrocarbon Receptor Pathway—TNF—acquired immunodeficiency syndrome	8.98e-05	0.00235	CbGpPWpGaD
Buprenorphine—Musculoskeletal discomfort—Saquinavir—acquired immunodeficiency syndrome	8.95e-05	0.000469	CcSEcCtD
Buprenorphine—ABCB1—lymph node—acquired immunodeficiency syndrome	8.95e-05	0.00255	CbGeAlD
Buprenorphine—Anorexia—Lamivudine—acquired immunodeficiency syndrome	8.94e-05	0.000468	CcSEcCtD
Buprenorphine—OPRL1—GPCR downstream signaling—CXCL12—acquired immunodeficiency syndrome	8.93e-05	0.00233	CbGpPWpGaD
Buprenorphine—OPRL1—GPCR downstream signaling—CXCR4—acquired immunodeficiency syndrome	8.93e-05	0.00233	CbGpPWpGaD
Buprenorphine—Insomnia—Saquinavir—acquired immunodeficiency syndrome	8.89e-05	0.000466	CcSEcCtD
Buprenorphine—Decreased appetite—Ritonavir—acquired immunodeficiency syndrome	8.88e-05	0.000465	CcSEcCtD
Buprenorphine—OPRD1—Class A/1 (Rhodopsin-like receptors)—CXCL12—acquired immunodeficiency syndrome	8.85e-05	0.00231	CbGpPWpGaD
Buprenorphine—OPRD1—Class A/1 (Rhodopsin-like receptors)—CXCR4—acquired immunodeficiency syndrome	8.85e-05	0.00231	CbGpPWpGaD
Buprenorphine—Nausea—Abacavir—acquired immunodeficiency syndrome	8.84e-05	0.000463	CcSEcCtD
Buprenorphine—Paraesthesia—Saquinavir—acquired immunodeficiency syndrome	8.82e-05	0.000462	CcSEcCtD
Buprenorphine—Gastrointestinal disorder—Ritonavir—acquired immunodeficiency syndrome	8.82e-05	0.000462	CcSEcCtD
Buprenorphine—OPRK1—Peptide ligand-binding receptors—CCL5—acquired immunodeficiency syndrome	8.81e-05	0.0023	CbGpPWpGaD
Buprenorphine—Fatigue—Ritonavir—acquired immunodeficiency syndrome	8.8e-05	0.000461	CcSEcCtD
Buprenorphine—OPRM1—G alpha (i) signalling events—CCR2—acquired immunodeficiency syndrome	8.78e-05	0.00229	CbGpPWpGaD
Buprenorphine—Urticaria—Delavirdine—acquired immunodeficiency syndrome	8.77e-05	0.00046	CcSEcCtD
Buprenorphine—Asthenia—Indinavir—acquired immunodeficiency syndrome	8.76e-05	0.000459	CcSEcCtD
Buprenorphine—Dyspnoea—Saquinavir—acquired immunodeficiency syndrome	8.76e-05	0.000459	CcSEcCtD
Buprenorphine—Hypotension—Lamivudine—acquired immunodeficiency syndrome	8.76e-05	0.000459	CcSEcCtD
Buprenorphine—Somnolence—Saquinavir—acquired immunodeficiency syndrome	8.74e-05	0.000458	CcSEcCtD
Buprenorphine—Constipation—Ritonavir—acquired immunodeficiency syndrome	8.73e-05	0.000457	CcSEcCtD
Buprenorphine—Pain—Ritonavir—acquired immunodeficiency syndrome	8.73e-05	0.000457	CcSEcCtD
Buprenorphine—Body temperature increased—Delavirdine—acquired immunodeficiency syndrome	8.73e-05	0.000457	CcSEcCtD
Buprenorphine—Abdominal pain—Delavirdine—acquired immunodeficiency syndrome	8.73e-05	0.000457	CcSEcCtD
Buprenorphine—Dizziness—Zidovudine—acquired immunodeficiency syndrome	8.69e-05	0.000455	CcSEcCtD
Buprenorphine—Dyspepsia—Saquinavir—acquired immunodeficiency syndrome	8.65e-05	0.000453	CcSEcCtD
Buprenorphine—Pruritus—Indinavir—acquired immunodeficiency syndrome	8.64e-05	0.000453	CcSEcCtD
Buprenorphine—OPRL1—Signaling by GPCR—CCR2—acquired immunodeficiency syndrome	8.62e-05	0.00225	CbGpPWpGaD
Buprenorphine—OPRM1—GPCR ligand binding—CCL4—acquired immunodeficiency syndrome	8.6e-05	0.00225	CbGpPWpGaD
Buprenorphine—Decreased appetite—Saquinavir—acquired immunodeficiency syndrome	8.54e-05	0.000448	CcSEcCtD
Buprenorphine—Musculoskeletal discomfort—Lamivudine—acquired immunodeficiency syndrome	8.54e-05	0.000447	CcSEcCtD
Buprenorphine—Hypersensitivity—Efavirenz—acquired immunodeficiency syndrome	8.5e-05	0.000445	CcSEcCtD
Buprenorphine—Gastrointestinal disorder—Saquinavir—acquired immunodeficiency syndrome	8.48e-05	0.000445	CcSEcCtD
Buprenorphine—Insomnia—Lamivudine—acquired immunodeficiency syndrome	8.48e-05	0.000444	CcSEcCtD
Buprenorphine—Fatigue—Saquinavir—acquired immunodeficiency syndrome	8.47e-05	0.000444	CcSEcCtD
Buprenorphine—OPRD1—G alpha (i) signalling events—CCL5—acquired immunodeficiency syndrome	8.47e-05	0.00221	CbGpPWpGaD
Buprenorphine—Paraesthesia—Lamivudine—acquired immunodeficiency syndrome	8.42e-05	0.000441	CcSEcCtD
Buprenorphine—Feeling abnormal—Ritonavir—acquired immunodeficiency syndrome	8.41e-05	0.000441	CcSEcCtD
Buprenorphine—Constipation—Saquinavir—acquired immunodeficiency syndrome	8.4e-05	0.00044	CcSEcCtD
Buprenorphine—Pain—Saquinavir—acquired immunodeficiency syndrome	8.4e-05	0.00044	CcSEcCtD
Buprenorphine—Dyspnoea—Lamivudine—acquired immunodeficiency syndrome	8.36e-05	0.000438	CcSEcCtD
Buprenorphine—Diarrhoea—Indinavir—acquired immunodeficiency syndrome	8.36e-05	0.000438	CcSEcCtD
Buprenorphine—Vomiting—Zidovudine—acquired immunodeficiency syndrome	8.35e-05	0.000437	CcSEcCtD
Buprenorphine—Gastrointestinal pain—Ritonavir—acquired immunodeficiency syndrome	8.35e-05	0.000437	CcSEcCtD
Buprenorphine—Somnolence—Lamivudine—acquired immunodeficiency syndrome	8.33e-05	0.000437	CcSEcCtD
Buprenorphine—Rash—Zidovudine—acquired immunodeficiency syndrome	8.28e-05	0.000434	CcSEcCtD
Buprenorphine—Asthenia—Efavirenz—acquired immunodeficiency syndrome	8.28e-05	0.000434	CcSEcCtD
Buprenorphine—Dermatitis—Zidovudine—acquired immunodeficiency syndrome	8.27e-05	0.000433	CcSEcCtD
Buprenorphine—OPRK1—Class A/1 (Rhodopsin-like receptors)—CCR2—acquired immunodeficiency syndrome	8.26e-05	0.00216	CbGpPWpGaD
Buprenorphine—OPRM1—G alpha (i) signalling events—CXCL12—acquired immunodeficiency syndrome	8.25e-05	0.00216	CbGpPWpGaD
Buprenorphine—OPRM1—G alpha (i) signalling events—CXCR4—acquired immunodeficiency syndrome	8.25e-05	0.00216	CbGpPWpGaD
Buprenorphine—Dyspepsia—Lamivudine—acquired immunodeficiency syndrome	8.25e-05	0.000432	CcSEcCtD
Buprenorphine—OPRL1—Signaling Pathways—CCL4—acquired immunodeficiency syndrome	8.24e-05	0.00215	CbGpPWpGaD
Buprenorphine—Headache—Zidovudine—acquired immunodeficiency syndrome	8.23e-05	0.000431	CcSEcCtD
Buprenorphine—Pruritus—Efavirenz—acquired immunodeficiency syndrome	8.16e-05	0.000428	CcSEcCtD
Buprenorphine—Decreased appetite—Lamivudine—acquired immunodeficiency syndrome	8.15e-05	0.000427	CcSEcCtD
Buprenorphine—OPRM1—GPCRs, Class A Rhodopsin-like—CCR2—acquired immunodeficiency syndrome	8.15e-05	0.00213	CbGpPWpGaD
Buprenorphine—Hypersensitivity—Delavirdine—acquired immunodeficiency syndrome	8.14e-05	0.000426	CcSEcCtD
Buprenorphine—Urticaria—Ritonavir—acquired immunodeficiency syndrome	8.11e-05	0.000425	CcSEcCtD
Buprenorphine—OPRL1—Signaling by GPCR—CXCL12—acquired immunodeficiency syndrome	8.11e-05	0.00212	CbGpPWpGaD
Buprenorphine—OPRL1—Signaling by GPCR—CXCR4—acquired immunodeficiency syndrome	8.11e-05	0.00212	CbGpPWpGaD
Buprenorphine—Feeling abnormal—Saquinavir—acquired immunodeficiency syndrome	8.1e-05	0.000424	CcSEcCtD
Buprenorphine—Gastrointestinal disorder—Lamivudine—acquired immunodeficiency syndrome	8.09e-05	0.000424	CcSEcCtD
Buprenorphine—Fatigue—Lamivudine—acquired immunodeficiency syndrome	8.08e-05	0.000423	CcSEcCtD
Buprenorphine—Dizziness—Indinavir—acquired immunodeficiency syndrome	8.08e-05	0.000423	CcSEcCtD
Buprenorphine—Body temperature increased—Ritonavir—acquired immunodeficiency syndrome	8.07e-05	0.000423	CcSEcCtD
Buprenorphine—Abdominal pain—Ritonavir—acquired immunodeficiency syndrome	8.07e-05	0.000423	CcSEcCtD
Buprenorphine—OPRM1—Signaling by GPCR—CCL3L1—acquired immunodeficiency syndrome	8.06e-05	0.00211	CbGpPWpGaD
Buprenorphine—Gastrointestinal pain—Saquinavir—acquired immunodeficiency syndrome	8.04e-05	0.000421	CcSEcCtD
Buprenorphine—Pain—Lamivudine—acquired immunodeficiency syndrome	8.02e-05	0.00042	CcSEcCtD
Buprenorphine—Constipation—Lamivudine—acquired immunodeficiency syndrome	8.02e-05	0.00042	CcSEcCtD
Buprenorphine—OPRK1—Peptide ligand-binding receptors—CCR5—acquired immunodeficiency syndrome	7.93e-05	0.00207	CbGpPWpGaD
Buprenorphine—OPRD1—GPCR ligand binding—CCL3—acquired immunodeficiency syndrome	7.93e-05	0.00207	CbGpPWpGaD
Buprenorphine—Asthenia—Delavirdine—acquired immunodeficiency syndrome	7.92e-05	0.000415	CcSEcCtD
Buprenorphine—Diarrhoea—Efavirenz—acquired immunodeficiency syndrome	7.9e-05	0.000414	CcSEcCtD
Buprenorphine—Pruritus—Delavirdine—acquired immunodeficiency syndrome	7.81e-05	0.000409	CcSEcCtD
Buprenorphine—Urticaria—Saquinavir—acquired immunodeficiency syndrome	7.81e-05	0.000409	CcSEcCtD
Buprenorphine—Nausea—Zidovudine—acquired immunodeficiency syndrome	7.8e-05	0.000409	CcSEcCtD
Buprenorphine—Abdominal pain—Saquinavir—acquired immunodeficiency syndrome	7.77e-05	0.000407	CcSEcCtD
Buprenorphine—Body temperature increased—Saquinavir—acquired immunodeficiency syndrome	7.77e-05	0.000407	CcSEcCtD
Buprenorphine—Vomiting—Indinavir—acquired immunodeficiency syndrome	7.77e-05	0.000407	CcSEcCtD
Buprenorphine—OPRK1—Class A/1 (Rhodopsin-like receptors)—CXCR4—acquired immunodeficiency syndrome	7.76e-05	0.00203	CbGpPWpGaD
Buprenorphine—OPRK1—Class A/1 (Rhodopsin-like receptors)—CXCL12—acquired immunodeficiency syndrome	7.76e-05	0.00203	CbGpPWpGaD
Buprenorphine—Feeling abnormal—Lamivudine—acquired immunodeficiency syndrome	7.73e-05	0.000405	CcSEcCtD
Buprenorphine—OPRM1—Class A/1 (Rhodopsin-like receptors)—CCL3—acquired immunodeficiency syndrome	7.72e-05	0.00202	CbGpPWpGaD
Buprenorphine—Rash—Indinavir—acquired immunodeficiency syndrome	7.7e-05	0.000403	CcSEcCtD
Buprenorphine—Dermatitis—Indinavir—acquired immunodeficiency syndrome	7.69e-05	0.000403	CcSEcCtD
Buprenorphine—Gastrointestinal pain—Lamivudine—acquired immunodeficiency syndrome	7.67e-05	0.000402	CcSEcCtD
Buprenorphine—OPRM1—GPCRs, Class A Rhodopsin-like—CXCR4—acquired immunodeficiency syndrome	7.66e-05	0.002	CbGpPWpGaD
Buprenorphine—OPRM1—TCR Signaling Pathway—CD4—acquired immunodeficiency syndrome	7.66e-05	0.002	CbGpPWpGaD
Buprenorphine—Headache—Indinavir—acquired immunodeficiency syndrome	7.65e-05	0.000401	CcSEcCtD
Buprenorphine—OPRD1—G alpha (i) signalling events—CCR5—acquired immunodeficiency syndrome	7.63e-05	0.002	CbGpPWpGaD
Buprenorphine—Dizziness—Efavirenz—acquired immunodeficiency syndrome	7.63e-05	0.0004	CcSEcCtD
Buprenorphine—Diarrhoea—Delavirdine—acquired immunodeficiency syndrome	7.55e-05	0.000396	CcSEcCtD
Buprenorphine—Hypersensitivity—Ritonavir—acquired immunodeficiency syndrome	7.52e-05	0.000394	CcSEcCtD
Buprenorphine—Urticaria—Lamivudine—acquired immunodeficiency syndrome	7.45e-05	0.00039	CcSEcCtD
Buprenorphine—OPRM1—Peptide ligand-binding receptors—CCL5—acquired immunodeficiency syndrome	7.44e-05	0.00195	CbGpPWpGaD
Buprenorphine—OPRK1—G alpha (i) signalling events—CCL5—acquired immunodeficiency syndrome	7.43e-05	0.00194	CbGpPWpGaD
Buprenorphine—Abdominal pain—Lamivudine—acquired immunodeficiency syndrome	7.41e-05	0.000388	CcSEcCtD
Buprenorphine—Body temperature increased—Lamivudine—acquired immunodeficiency syndrome	7.41e-05	0.000388	CcSEcCtD
Buprenorphine—Vomiting—Efavirenz—acquired immunodeficiency syndrome	7.34e-05	0.000384	CcSEcCtD
Buprenorphine—Asthenia—Ritonavir—acquired immunodeficiency syndrome	7.33e-05	0.000384	CcSEcCtD
Buprenorphine—Dizziness—Delavirdine—acquired immunodeficiency syndrome	7.3e-05	0.000383	CcSEcCtD
Buprenorphine—Rash—Efavirenz—acquired immunodeficiency syndrome	7.28e-05	0.000381	CcSEcCtD
Buprenorphine—Dermatitis—Efavirenz—acquired immunodeficiency syndrome	7.27e-05	0.000381	CcSEcCtD
Buprenorphine—Nausea—Indinavir—acquired immunodeficiency syndrome	7.26e-05	0.00038	CcSEcCtD
Buprenorphine—Hypersensitivity—Saquinavir—acquired immunodeficiency syndrome	7.24e-05	0.000379	CcSEcCtD
Buprenorphine—Headache—Efavirenz—acquired immunodeficiency syndrome	7.23e-05	0.000379	CcSEcCtD
Buprenorphine—Pruritus—Ritonavir—acquired immunodeficiency syndrome	7.22e-05	0.000378	CcSEcCtD
Buprenorphine—OPRD1—GPCR ligand binding—CCR2—acquired immunodeficiency syndrome	7.17e-05	0.00187	CbGpPWpGaD
Buprenorphine—OPRD1—GPCRs, Class A Rhodopsin-like—CCR5—acquired immunodeficiency syndrome	7.08e-05	0.00185	CbGpPWpGaD
Buprenorphine—Asthenia—Saquinavir—acquired immunodeficiency syndrome	7.05e-05	0.000369	CcSEcCtD
Buprenorphine—Vomiting—Delavirdine—acquired immunodeficiency syndrome	7.02e-05	0.000368	CcSEcCtD
Buprenorphine—ABCB1—Allograft Rejection—IL10—acquired immunodeficiency syndrome	7.02e-05	0.00183	CbGpPWpGaD
Buprenorphine—ABCB1—Allograft Rejection—CD40LG—acquired immunodeficiency syndrome	7.02e-05	0.00183	CbGpPWpGaD
Buprenorphine—Diarrhoea—Ritonavir—acquired immunodeficiency syndrome	6.99e-05	0.000366	CcSEcCtD
Buprenorphine—OPRM1—Class A/1 (Rhodopsin-like receptors)—CCR2—acquired immunodeficiency syndrome	6.98e-05	0.00182	CbGpPWpGaD
Buprenorphine—Rash—Delavirdine—acquired immunodeficiency syndrome	6.96e-05	0.000365	CcSEcCtD
Buprenorphine—Dermatitis—Delavirdine—acquired immunodeficiency syndrome	6.96e-05	0.000364	CcSEcCtD
Buprenorphine—OPRK1—GPCR ligand binding—CCL3—acquired immunodeficiency syndrome	6.95e-05	0.00182	CbGpPWpGaD
Buprenorphine—Pruritus—Saquinavir—acquired immunodeficiency syndrome	6.95e-05	0.000364	CcSEcCtD
Buprenorphine—Headache—Delavirdine—acquired immunodeficiency syndrome	6.92e-05	0.000362	CcSEcCtD
Buprenorphine—Hypersensitivity—Lamivudine—acquired immunodeficiency syndrome	6.91e-05	0.000362	CcSEcCtD
Buprenorphine—OPRL1—Circadian rythm related genes—IL6—acquired immunodeficiency syndrome	6.88e-05	0.0018	CbGpPWpGaD
Buprenorphine—Nausea—Efavirenz—acquired immunodeficiency syndrome	6.85e-05	0.000359	CcSEcCtD
Buprenorphine—ABCB1—Allograft Rejection—IL4—acquired immunodeficiency syndrome	6.83e-05	0.00178	CbGpPWpGaD
Buprenorphine—OPRL1—GPCR downstream signaling—CCL5—acquired immunodeficiency syndrome	6.79e-05	0.00178	CbGpPWpGaD
Buprenorphine—Dizziness—Ritonavir—acquired immunodeficiency syndrome	6.75e-05	0.000354	CcSEcCtD
Buprenorphine—OPRD1—GPCR ligand binding—CXCL12—acquired immunodeficiency syndrome	6.74e-05	0.00176	CbGpPWpGaD
Buprenorphine—OPRD1—GPCR ligand binding—CXCR4—acquired immunodeficiency syndrome	6.74e-05	0.00176	CbGpPWpGaD
Buprenorphine—OPRD1—Class A/1 (Rhodopsin-like receptors)—CCL5—acquired immunodeficiency syndrome	6.74e-05	0.00176	CbGpPWpGaD
Buprenorphine—Asthenia—Lamivudine—acquired immunodeficiency syndrome	6.73e-05	0.000352	CcSEcCtD
Buprenorphine—Diarrhoea—Saquinavir—acquired immunodeficiency syndrome	6.72e-05	0.000352	CcSEcCtD
Buprenorphine—OPRM1—Peptide ligand-binding receptors—CCR5—acquired immunodeficiency syndrome	6.71e-05	0.00175	CbGpPWpGaD
Buprenorphine—OPRK1—G alpha (i) signalling events—CCR5—acquired immunodeficiency syndrome	6.69e-05	0.00175	CbGpPWpGaD
Buprenorphine—OPRL1—GPCR downstream signaling—CSF2—acquired immunodeficiency syndrome	6.69e-05	0.00175	CbGpPWpGaD
Buprenorphine—ABCB1—Allograft Rejection—HLA-B—acquired immunodeficiency syndrome	6.68e-05	0.00174	CbGpPWpGaD
Buprenorphine—Pruritus—Lamivudine—acquired immunodeficiency syndrome	6.63e-05	0.000348	CcSEcCtD
Buprenorphine—OPRD1—Signaling by GPCR—ACKR1—acquired immunodeficiency syndrome	6.59e-05	0.00172	CbGpPWpGaD
Buprenorphine—CYP2C18—Metabolism—TAT—acquired immunodeficiency syndrome	6.56e-05	0.00172	CbGpPWpGaD
Buprenorphine—OPRM1—Class A/1 (Rhodopsin-like receptors)—CXCR4—acquired immunodeficiency syndrome	6.56e-05	0.00172	CbGpPWpGaD
Buprenorphine—OPRM1—Class A/1 (Rhodopsin-like receptors)—CXCL12—acquired immunodeficiency syndrome	6.56e-05	0.00172	CbGpPWpGaD
Buprenorphine—Nausea—Delavirdine—acquired immunodeficiency syndrome	6.56e-05	0.000344	CcSEcCtD
Buprenorphine—Dizziness—Saquinavir—acquired immunodeficiency syndrome	6.5e-05	0.00034	CcSEcCtD
Buprenorphine—Vomiting—Ritonavir—acquired immunodeficiency syndrome	6.49e-05	0.00034	CcSEcCtD
Buprenorphine—Rash—Ritonavir—acquired immunodeficiency syndrome	6.44e-05	0.000337	CcSEcCtD
Buprenorphine—Dermatitis—Ritonavir—acquired immunodeficiency syndrome	6.43e-05	0.000337	CcSEcCtD
Buprenorphine—OPRD1—Signaling Pathways—CCL3L1—acquired immunodeficiency syndrome	6.42e-05	0.00168	CbGpPWpGaD
Buprenorphine—Diarrhoea—Lamivudine—acquired immunodeficiency syndrome	6.41e-05	0.000336	CcSEcCtD
Buprenorphine—Headache—Ritonavir—acquired immunodeficiency syndrome	6.4e-05	0.000335	CcSEcCtD
Buprenorphine—OPRK1—GPCR ligand binding—CCR2—acquired immunodeficiency syndrome	6.29e-05	0.00164	CbGpPWpGaD
Buprenorphine—OPRM1—G alpha (i) signalling events—CCL5—acquired immunodeficiency syndrome	6.28e-05	0.00164	CbGpPWpGaD
Buprenorphine—Vomiting—Saquinavir—acquired immunodeficiency syndrome	6.25e-05	0.000327	CcSEcCtD
Buprenorphine—OPRK1—GPCRs, Class A Rhodopsin-like—CCR5—acquired immunodeficiency syndrome	6.21e-05	0.00162	CbGpPWpGaD
Buprenorphine—Dizziness—Lamivudine—acquired immunodeficiency syndrome	6.2e-05	0.000325	CcSEcCtD
Buprenorphine—Rash—Saquinavir—acquired immunodeficiency syndrome	6.2e-05	0.000325	CcSEcCtD
Buprenorphine—Dermatitis—Saquinavir—acquired immunodeficiency syndrome	6.19e-05	0.000324	CcSEcCtD
Buprenorphine—OPRL1—Signaling by GPCR—CCL5—acquired immunodeficiency syndrome	6.17e-05	0.00161	CbGpPWpGaD
Buprenorphine—Headache—Saquinavir—acquired immunodeficiency syndrome	6.16e-05	0.000323	CcSEcCtD
Buprenorphine—OPRL1—GPCR downstream signaling—CCR5—acquired immunodeficiency syndrome	6.12e-05	0.0016	CbGpPWpGaD
Buprenorphine—OPRL1—Signaling by GPCR—CSF2—acquired immunodeficiency syndrome	6.07e-05	0.00159	CbGpPWpGaD
Buprenorphine—OPRD1—Class A/1 (Rhodopsin-like receptors)—CCR5—acquired immunodeficiency syndrome	6.07e-05	0.00159	CbGpPWpGaD
Buprenorphine—Nausea—Ritonavir—acquired immunodeficiency syndrome	6.07e-05	0.000318	CcSEcCtD
Buprenorphine—Vomiting—Lamivudine—acquired immunodeficiency syndrome	5.96e-05	0.000312	CcSEcCtD
Buprenorphine—OPRD1—Signaling by GPCR—CCL4—acquired immunodeficiency syndrome	5.96e-05	0.00156	CbGpPWpGaD
Buprenorphine—OPRK1—GPCR ligand binding—CXCR4—acquired immunodeficiency syndrome	5.91e-05	0.00155	CbGpPWpGaD
Buprenorphine—OPRK1—GPCR ligand binding—CXCL12—acquired immunodeficiency syndrome	5.91e-05	0.00155	CbGpPWpGaD
Buprenorphine—Rash—Lamivudine—acquired immunodeficiency syndrome	5.91e-05	0.00031	CcSEcCtD
Buprenorphine—OPRK1—Class A/1 (Rhodopsin-like receptors)—CCL5—acquired immunodeficiency syndrome	5.91e-05	0.00154	CbGpPWpGaD
Buprenorphine—Dermatitis—Lamivudine—acquired immunodeficiency syndrome	5.91e-05	0.000309	CcSEcCtD
Buprenorphine—OPRM1—GPCR ligand binding—CCL3—acquired immunodeficiency syndrome	5.88e-05	0.00154	CbGpPWpGaD
Buprenorphine—Headache—Lamivudine—acquired immunodeficiency syndrome	5.87e-05	0.000308	CcSEcCtD
Buprenorphine—Nausea—Saquinavir—acquired immunodeficiency syndrome	5.84e-05	0.000306	CcSEcCtD
Buprenorphine—OPRK1—Signaling by GPCR—ACKR1—acquired immunodeficiency syndrome	5.78e-05	0.00151	CbGpPWpGaD
Buprenorphine—OPRM1—G alpha (i) signalling events—CCR5—acquired immunodeficiency syndrome	5.66e-05	0.00148	CbGpPWpGaD
Buprenorphine—OPRL1—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	5.63e-05	0.00147	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—CCL3L1—acquired immunodeficiency syndrome	5.63e-05	0.00147	CbGpPWpGaD
Buprenorphine—CYP2C18—Metabolism—AGPS—acquired immunodeficiency syndrome	5.58e-05	0.00146	CbGpPWpGaD
Buprenorphine—Nausea—Lamivudine—acquired immunodeficiency syndrome	5.57e-05	0.000292	CcSEcCtD
Buprenorphine—OPRL1—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	5.56e-05	0.00145	CbGpPWpGaD
Buprenorphine—OPRK1—Class A/1 (Rhodopsin-like receptors)—CCR5—acquired immunodeficiency syndrome	5.32e-05	0.00139	CbGpPWpGaD
Buprenorphine—OPRM1—GPCR ligand binding—CCR2—acquired immunodeficiency syndrome	5.31e-05	0.00139	CbGpPWpGaD
Buprenorphine—OPRM1—GPCRs, Class A Rhodopsin-like—CCR5—acquired immunodeficiency syndrome	5.25e-05	0.00137	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling by GPCR—CCL4—acquired immunodeficiency syndrome	5.22e-05	0.00137	CbGpPWpGaD
Buprenorphine—CYP2C8—Metabolism of lipids and lipoproteins—AGPS—acquired immunodeficiency syndrome	5.22e-05	0.00136	CbGpPWpGaD
Buprenorphine—UGT1A9—Metabolism—TAT—acquired immunodeficiency syndrome	5.19e-05	0.00136	CbGpPWpGaD
Buprenorphine—OPRD1—GPCR ligand binding—CCL5—acquired immunodeficiency syndrome	5.13e-05	0.00134	CbGpPWpGaD
Buprenorphine—OPRL1—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	5.09e-05	0.00133	CbGpPWpGaD
Buprenorphine—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IFNG—acquired immunodeficiency syndrome	5.08e-05	0.00133	CbGpPWpGaD
Buprenorphine—OPRM1—GPCR ligand binding—CXCL12—acquired immunodeficiency syndrome	5e-05	0.00131	CbGpPWpGaD
Buprenorphine—OPRM1—GPCR ligand binding—CXCR4—acquired immunodeficiency syndrome	5e-05	0.00131	CbGpPWpGaD
Buprenorphine—OPRM1—Class A/1 (Rhodopsin-like receptors)—CCL5—acquired immunodeficiency syndrome	4.99e-05	0.0013	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling by GPCR—ACKR1—acquired immunodeficiency syndrome	4.88e-05	0.00128	CbGpPWpGaD
Buprenorphine—OPRL1—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	4.79e-05	0.00125	CbGpPWpGaD
Buprenorphine—OPRL1—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	4.79e-05	0.00125	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—CCL3L1—acquired immunodeficiency syndrome	4.76e-05	0.00124	CbGpPWpGaD
Buprenorphine—CYP2C19—Metabolism of lipids and lipoproteins—AGPS—acquired immunodeficiency syndrome	4.66e-05	0.00122	CbGpPWpGaD
Buprenorphine—OPRD1—GPCR ligand binding—CCR5—acquired immunodeficiency syndrome	4.62e-05	0.00121	CbGpPWpGaD
Buprenorphine—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IL2—acquired immunodeficiency syndrome	4.51e-05	0.00118	CbGpPWpGaD
Buprenorphine—OPRK1—GPCR ligand binding—CCL5—acquired immunodeficiency syndrome	4.5e-05	0.00118	CbGpPWpGaD
Buprenorphine—OPRM1—Class A/1 (Rhodopsin-like receptors)—CCR5—acquired immunodeficiency syndrome	4.5e-05	0.00118	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling by GPCR—CCL4—acquired immunodeficiency syndrome	4.41e-05	0.00115	CbGpPWpGaD
Buprenorphine—UGT1A9—Metabolism—AGPS—acquired immunodeficiency syndrome	4.41e-05	0.00115	CbGpPWpGaD
Buprenorphine—ABCG2—Metabolism—TAT—acquired immunodeficiency syndrome	4.4e-05	0.00115	CbGpPWpGaD
Buprenorphine—CYP3A7—Metabolism—TAT—acquired immunodeficiency syndrome	4.36e-05	0.00114	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism of lipids and lipoproteins—AGPS—acquired immunodeficiency syndrome	4.25e-05	0.00111	CbGpPWpGaD
Buprenorphine—OPRM1—TCR Signaling Pathway—IL6—acquired immunodeficiency syndrome	4.14e-05	0.00108	CbGpPWpGaD
Buprenorphine—ABCB1—Allograft Rejection—IFNG—acquired immunodeficiency syndrome	4.13e-05	0.00108	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling by GPCR—CCL3—acquired immunodeficiency syndrome	4.07e-05	0.00106	CbGpPWpGaD
Buprenorphine—OPRD1—GPCR downstream signaling—CCR2—acquired immunodeficiency syndrome	4.05e-05	0.00106	CbGpPWpGaD
Buprenorphine—OPRK1—GPCR ligand binding—CCR5—acquired immunodeficiency syndrome	4.05e-05	0.00106	CbGpPWpGaD
Buprenorphine—CYP2A6—Metabolism—TAT—acquired immunodeficiency syndrome	4e-05	0.00105	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—ACKR1—acquired immunodeficiency syndrome	3.89e-05	0.00102	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—CCNT1—acquired immunodeficiency syndrome	3.89e-05	0.00102	CbGpPWpGaD
Buprenorphine—OPRD1—GPCR downstream signaling—CXCR4—acquired immunodeficiency syndrome	3.81e-05	0.000996	CbGpPWpGaD
Buprenorphine—OPRD1—GPCR downstream signaling—CXCL12—acquired immunodeficiency syndrome	3.81e-05	0.000996	CbGpPWpGaD
Buprenorphine—OPRM1—GPCR ligand binding—CCL5—acquired immunodeficiency syndrome	3.8e-05	0.000994	CbGpPWpGaD
Buprenorphine—ABCG2—Metabolism—AGPS—acquired immunodeficiency syndrome	3.74e-05	0.000978	CbGpPWpGaD
Buprenorphine—CYP3A7—Metabolism—AGPS—acquired immunodeficiency syndrome	3.71e-05	0.00097	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling by GPCR—CCR2—acquired immunodeficiency syndrome	3.68e-05	0.000962	CbGpPWpGaD
Buprenorphine—ABCB1—Allograft Rejection—IL2—acquired immunodeficiency syndrome	3.67e-05	0.000959	CbGpPWpGaD
Buprenorphine—OPRL1—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	3.64e-05	0.000952	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism of lipids and lipoproteins—AGPS—acquired immunodeficiency syndrome	3.63e-05	0.000948	CbGpPWpGaD
Buprenorphine—OPRL1—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	3.59e-05	0.000938	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling by GPCR—CCL3—acquired immunodeficiency syndrome	3.57e-05	0.000933	CbGpPWpGaD
Buprenorphine—OPRK1—GPCR downstream signaling—CCR2—acquired immunodeficiency syndrome	3.55e-05	0.000929	CbGpPWpGaD
Buprenorphine—OPRL1—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	3.54e-05	0.000924	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—CCL4—acquired immunodeficiency syndrome	3.52e-05	0.00092	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling by GPCR—CXCR4—acquired immunodeficiency syndrome	3.46e-05	0.000905	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling by GPCR—CXCL12—acquired immunodeficiency syndrome	3.46e-05	0.000905	CbGpPWpGaD
Buprenorphine—OPRM1—GPCR ligand binding—CCR5—acquired immunodeficiency syndrome	3.42e-05	0.000895	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—ACKR1—acquired immunodeficiency syndrome	3.41e-05	0.000892	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—CCNT1—acquired immunodeficiency syndrome	3.41e-05	0.000892	CbGpPWpGaD
Buprenorphine—CYP2A6—Metabolism—AGPS—acquired immunodeficiency syndrome	3.4e-05	0.000889	CbGpPWpGaD
Buprenorphine—OPRK1—GPCR downstream signaling—CXCL12—acquired immunodeficiency syndrome	3.34e-05	0.000873	CbGpPWpGaD
Buprenorphine—OPRK1—GPCR downstream signaling—CXCR4—acquired immunodeficiency syndrome	3.34e-05	0.000873	CbGpPWpGaD
Buprenorphine—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TNF—acquired immunodeficiency syndrome	3.29e-05	0.000859	CbGpPWpGaD
Buprenorphine—CYP1A2—Aryl Hydrocarbon Receptor—TNF—acquired immunodeficiency syndrome	3.29e-05	0.000859	CbGpPWpGaD
Buprenorphine—OPRL1—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	3.28e-05	0.000858	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling by GPCR—CCR2—acquired immunodeficiency syndrome	3.23e-05	0.000844	CbGpPWpGaD
Buprenorphine—OPRL1—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	3.21e-05	0.000839	CbGpPWpGaD
Buprenorphine—CYP3A5—Metabolism—TAT—acquired immunodeficiency syndrome	3.15e-05	0.000825	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—CCL4—acquired immunodeficiency syndrome	3.09e-05	0.000807	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling by GPCR—CXCL12—acquired immunodeficiency syndrome	3.03e-05	0.000793	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling by GPCR—CXCR4—acquired immunodeficiency syndrome	3.03e-05	0.000793	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling by GPCR—CCL3—acquired immunodeficiency syndrome	3.02e-05	0.000788	CbGpPWpGaD
Buprenorphine—OPRM1—GPCR downstream signaling—CCR2—acquired immunodeficiency syndrome	3e-05	0.000785	CbGpPWpGaD
Buprenorphine—OPRD1—GPCR downstream signaling—CCL5—acquired immunodeficiency syndrome	2.9e-05	0.000758	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—CCNT1—acquired immunodeficiency syndrome	2.88e-05	0.000754	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—ACKR1—acquired immunodeficiency syndrome	2.88e-05	0.000754	CbGpPWpGaD
Buprenorphine—OPRD1—GPCR downstream signaling—CSF2—acquired immunodeficiency syndrome	2.86e-05	0.000746	CbGpPWpGaD
Buprenorphine—OPRM1—GPCR downstream signaling—CXCR4—acquired immunodeficiency syndrome	2.82e-05	0.000738	CbGpPWpGaD
Buprenorphine—OPRM1—GPCR downstream signaling—CXCL12—acquired immunodeficiency syndrome	2.82e-05	0.000738	CbGpPWpGaD
Buprenorphine—CYP2C8—Metabolism—TAT—acquired immunodeficiency syndrome	2.73e-05	0.000714	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling by GPCR—CCR2—acquired immunodeficiency syndrome	2.73e-05	0.000713	CbGpPWpGaD
Buprenorphine—CYP3A5—Metabolism—AGPS—acquired immunodeficiency syndrome	2.68e-05	0.000701	CbGpPWpGaD
Buprenorphine—ABCB1—Allograft Rejection—TNF—acquired immunodeficiency syndrome	2.67e-05	0.000698	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling by GPCR—CCL5—acquired immunodeficiency syndrome	2.63e-05	0.000688	CbGpPWpGaD
Buprenorphine—OPRD1—GPCR downstream signaling—CCR5—acquired immunodeficiency syndrome	2.61e-05	0.000683	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—CCL4—acquired immunodeficiency syndrome	2.61e-05	0.000682	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling by GPCR—CSF2—acquired immunodeficiency syndrome	2.59e-05	0.000678	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling by GPCR—CXCR4—acquired immunodeficiency syndrome	2.56e-05	0.00067	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling by GPCR—CXCL12—acquired immunodeficiency syndrome	2.56e-05	0.00067	CbGpPWpGaD
Buprenorphine—OPRK1—GPCR downstream signaling—CCL5—acquired immunodeficiency syndrome	2.54e-05	0.000664	CbGpPWpGaD
Buprenorphine—OPRK1—GPCR downstream signaling—CSF2—acquired immunodeficiency syndrome	2.5e-05	0.000654	CbGpPWpGaD
Buprenorphine—CYP2C19—Metabolism—TAT—acquired immunodeficiency syndrome	2.44e-05	0.000637	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	2.4e-05	0.000628	CbGpPWpGaD
Buprenorphine—ABCB1—Metabolism—TAT—acquired immunodeficiency syndrome	2.38e-05	0.000622	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	2.37e-05	0.00062	CbGpPWpGaD
Buprenorphine—CYP2C8—Metabolism—AGPS—acquired immunodeficiency syndrome	2.32e-05	0.000607	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling by GPCR—CCL5—acquired immunodeficiency syndrome	2.31e-05	0.000603	CbGpPWpGaD
Buprenorphine—OPRK1—GPCR downstream signaling—CCR5—acquired immunodeficiency syndrome	2.29e-05	0.000599	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling by GPCR—CSF2—acquired immunodeficiency syndrome	2.27e-05	0.000594	CbGpPWpGaD
Buprenorphine—CYP2D6—Metabolism—TAT—acquired immunodeficiency syndrome	2.24e-05	0.000586	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism—TAT—acquired immunodeficiency syndrome	2.22e-05	0.000581	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	2.17e-05	0.000568	CbGpPWpGaD
Buprenorphine—OPRM1—GPCR downstream signaling—CCL5—acquired immunodeficiency syndrome	2.15e-05	0.000562	CbGpPWpGaD
Buprenorphine—OPRM1—GPCR downstream signaling—CSF2—acquired immunodeficiency syndrome	2.12e-05	0.000553	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	2.11e-05	0.000551	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	2.08e-05	0.000544	CbGpPWpGaD
Buprenorphine—CYP2C19—Metabolism—AGPS—acquired immunodeficiency syndrome	2.07e-05	0.000542	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	2.04e-05	0.000534	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	2.04e-05	0.000534	CbGpPWpGaD
Buprenorphine—UGT1A9—Metabolism of lipids and lipoproteins—ALB—acquired immunodeficiency syndrome	2.03e-05	0.000531	CbGpPWpGaD
Buprenorphine—ABCB1—Metabolism—AGPS—acquired immunodeficiency syndrome	2.02e-05	0.000529	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling by GPCR—CCL5—acquired immunodeficiency syndrome	1.95e-05	0.00051	CbGpPWpGaD
Buprenorphine—OPRM1—GPCR downstream signaling—CCR5—acquired immunodeficiency syndrome	1.94e-05	0.000506	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling by GPCR—CSF2—acquired immunodeficiency syndrome	1.92e-05	0.000502	CbGpPWpGaD
Buprenorphine—CYP2D6—Metabolism—AGPS—acquired immunodeficiency syndrome	1.91e-05	0.000499	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	1.91e-05	0.000498	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism—TAT—acquired immunodeficiency syndrome	1.9e-05	0.000497	CbGpPWpGaD
Buprenorphine—OPRL1—Signaling Pathways—IL2—acquired immunodeficiency syndrome	1.9e-05	0.000496	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism—AGPS—acquired immunodeficiency syndrome	1.89e-05	0.000494	CbGpPWpGaD
Buprenorphine—OPRL1—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	1.89e-05	0.000493	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	1.79e-05	0.000469	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	1.79e-05	0.000469	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	1.78e-05	0.000466	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	1.76e-05	0.000459	CbGpPWpGaD
Buprenorphine—ABCG2—Transmembrane transport of small molecules—ALB—acquired immunodeficiency syndrome	1.64e-05	0.000428	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism—AGPS—acquired immunodeficiency syndrome	1.62e-05	0.000422	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	1.61e-05	0.000421	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	1.56e-05	0.000406	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	1.53e-05	0.0004	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	1.51e-05	0.000396	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	1.51e-05	0.000396	CbGpPWpGaD
Buprenorphine—OPRD1—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	1.51e-05	0.000394	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—TAT—acquired immunodeficiency syndrome	1.47e-05	0.000383	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	1.4e-05	0.000366	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	1.37e-05	0.000358	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	1.36e-05	0.000356	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	1.34e-05	0.000351	CbGpPWpGaD
Buprenorphine—OPRK1—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	1.32e-05	0.000346	CbGpPWpGaD
Buprenorphine—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—acquired immunodeficiency syndrome	1.32e-05	0.000345	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—AGPS—acquired immunodeficiency syndrome	1.25e-05	0.000326	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	1.23e-05	0.000321	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	1.2e-05	0.000314	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	1.15e-05	0.000301	CbGpPWpGaD
Buprenorphine—CYP2C18—Metabolism—ALB—acquired immunodeficiency syndrome	1.14e-05	0.000299	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	1.14e-05	0.000297	CbGpPWpGaD
Buprenorphine—OPRM1—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	1.12e-05	0.000292	CbGpPWpGaD
Buprenorphine—OPRL1—Signaling Pathways—IL6—acquired immunodeficiency syndrome	1.11e-05	0.000291	CbGpPWpGaD
Buprenorphine—CYP2C8—Metabolism of lipids and lipoproteins—ALB—acquired immunodeficiency syndrome	1.07e-05	0.00028	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	1.04e-05	0.000271	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	1.02e-05	0.000265	CbGpPWpGaD
Buprenorphine—CYP2C19—Metabolism of lipids and lipoproteins—ALB—acquired immunodeficiency syndrome	9.55e-06	0.00025	CbGpPWpGaD
Buprenorphine—UGT1A9—Metabolism—ALB—acquired immunodeficiency syndrome	9.05e-06	0.000237	CbGpPWpGaD
Buprenorphine—ABCB1—Transmembrane transport of small molecules—ALB—acquired immunodeficiency syndrome	8.86e-06	0.000232	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism of lipids and lipoproteins—ALB—acquired immunodeficiency syndrome	8.71e-06	0.000228	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—IL2—acquired immunodeficiency syndrome	8.1e-06	0.000212	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	8.05e-06	0.000211	CbGpPWpGaD
Buprenorphine—ABCG2—Metabolism—ALB—acquired immunodeficiency syndrome	7.68e-06	0.000201	CbGpPWpGaD
Buprenorphine—CYP3A7—Metabolism—ALB—acquired immunodeficiency syndrome	7.61e-06	0.000199	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism of lipids and lipoproteins—ALB—acquired immunodeficiency syndrome	7.44e-06	0.000194	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—IL2—acquired immunodeficiency syndrome	7.1e-06	0.000186	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	7.06e-06	0.000185	CbGpPWpGaD
Buprenorphine—CYP2A6—Metabolism—ALB—acquired immunodeficiency syndrome	6.97e-06	0.000182	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—IL2—acquired immunodeficiency syndrome	6e-06	0.000157	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	5.97e-06	0.000156	CbGpPWpGaD
Buprenorphine—CYP3A5—Metabolism—ALB—acquired immunodeficiency syndrome	5.5e-06	0.000144	CbGpPWpGaD
Buprenorphine—CYP2C8—Metabolism—ALB—acquired immunodeficiency syndrome	4.76e-06	0.000125	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—IL6—acquired immunodeficiency syndrome	4.76e-06	0.000124	CbGpPWpGaD
Buprenorphine—CYP2C19—Metabolism—ALB—acquired immunodeficiency syndrome	4.25e-06	0.000111	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—IL6—acquired immunodeficiency syndrome	4.17e-06	0.000109	CbGpPWpGaD
Buprenorphine—ABCB1—Metabolism—ALB—acquired immunodeficiency syndrome	4.15e-06	0.000108	CbGpPWpGaD
Buprenorphine—CYP2D6—Metabolism—ALB—acquired immunodeficiency syndrome	3.91e-06	0.000102	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism—ALB—acquired immunodeficiency syndrome	3.88e-06	0.000101	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—IL6—acquired immunodeficiency syndrome	3.53e-06	9.22e-05	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism—ALB—acquired immunodeficiency syndrome	3.31e-06	8.66e-05	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—ALB—acquired immunodeficiency syndrome	2.56e-06	6.68e-05	CbGpPWpGaD
